The protooncogene Ets-1 is a transcription factor that is known to regulate certain matrix metalloproteinases and plasminogen activator, which have been associated with malignant behaviors in solid carcinomas. We hypothesized that Ets-1 expression is also associated with tumor progression and a worse prognosis in lung carcinoma patients. To clarify the role of the Ets-1 proto-oncogene, the expression of Ets-1 in non-small cell lung carcinomas using 156 paraffin-embedded specimens was determined in surgically resected tissue samples. Immunohistochemical staining showed Ets-1 expression in 82 cases of 156 carcinomas (53%): 36 of 52 (69%) squamous cell carcinomas, 41 of 96 (43%) adenocarcinomas, and 5 of 8 (63%) other carcinomas. In adenocarcinomas, a higher proportion of acinar type expressed Ets-1 compared to papillary or alveolar type ( p < 0.05). The proportion of adenocarcinoma that expressed Ets-1 increased with poorer histologic differentiation of the adenocarcinoma ( p < 0.05). Ets-1 positive adenocarcinomas had a larger mean size than Ets-1 negative adenocarcinomas ( p < 0.01). In adenocarcinoma patients, expression of Ets-1 was associated with disease-free ( p = 0.09) and overall survivals ( p < 0.05) after lung resection. Such relationship was not observed among squamous cell carcinoma patients. Our findings indicate that Ets-1 expression is related to histopathological differentiation, morphogenesis, and tumor progression of lung adenocarcinomas. Ets-1 appears to be a useful predictor of poor prognosis after surgical resection in lung adenocarcinoma patients. Ets-1 expression could be used to evaluate the malignant behaviors of lung adenocarcinomas.
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The incidence of lung cancer is relatively high and progressively increasing throughout the world. The prognosis of lung cancer correlates with histopathological type and differentiation (Takise et al. 1988) . The development and progression of carcinoma is thought to follow a series pathological type, clinical features and patient prognosis after resection.
MATERIALS AND METHODS

Patients and surgical specimens
We studied 156 primary human lung carcinomas obtained from 123 men and 33 women, with a mean age of 65 years (range; 19 to 84 years). Histopathologically, they included 96 adenocarcinomas, 52 squamous cell carcinomas, 6 large cell carcinomas, and 2 adenosquamous cell carcinomas. Informed consent was obtained from each subject. Tumor specimens were obtained from patients who were treated surgically at Nagasaki U n i v e r s i t y H o s p i t a l b e t w e e n 1 9 9 4 a n d 1 9 9 6 . Histopathological diagnosis of lung cancer was based on World Health Organization (WHO) histological typing of lung tumors (WHO 2004) . In some cases, immunohistochemical examination, including epithelial membrane antigen (EMA), keratin, chromogranin A, and carcinoembryonic antigen (CEA), were also included for tumor typing. Tumors with invasion of the visceral pleura were classified as pleural invasion positive cases using elastin-fiber staining (Elastica van Gieson staining). Histopathological diagnosis including tumor-nodemetastasis (TMN)-staging by the General Rule for Clinical and Pathological Record of Lung Carcinoma (the Japan Lung Cancer Society 2003) was established by two independent pathologists (E.Y., T.N.) and questionable cases were excluded from the final analysis. In cases classified as stage IV, total surgical resection of multiple tumors in different lung lobes (= intrapulmonary metastasis) in the same side lung is possible, which is considered a "complete resection" by the General Rule for Clinical and Pathological Record of Lung Carcinoma. An informed consent concerning research work using tissue specimens was obtained from each patient.
Immunohistochemistry
Each lung specimen was fixed in 10% formalin immediately after surgical excision and embedded in paraffin, then cut at a later stage into 4 μ m-thick sections. After deparaffinization in xylene, the sample was rehydrated in phosphate-buffered saline (FBS). In order to prevent non-specific binding, specimens were preincubated with normal bovine serum. The sample was incubated overnight with 0.1 μ g/ml of the primary polyclonal antibody against human c-Ets-1 (C-20, antibody against the C-terminal domains of Ets-1 protein, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at 4°C. After of genetic events affecting the structure and/or expression of various oncogenes, anti-oncogenes and growth factors. However, the mechanism of lung carcinogenesis is not fully understood.
Ets-1 (c-Ets-1), a cellular homologue of avian leukemic E26 retroviral oncogene (v-ets) (Leprince et al. 1983) , is a transcription factor that binds to a specific site on DNA, designated Ets-binding site (EBS) (Pognonec et al. 1989; Bosselut et al. 1990; Ho et al. 1990 ). Ets-family of transcription factors has a conserved "Ets-domain", which contains a unique helixturn-helix structure, which is the DNA-binding element (Watson et al. 1988) . Ets family genes are expressed during the embryonic period, and are associated with morphogenesis such as organ formation (Kola et al. 1993) . Furthermore, Ets-1 plays an important role in the regulation of various physiological processes such as cell proliferation and differentiation (Lewin 1991) . It is also thought to be associated with the growth of carcinomas through the regulation of transcription of matrix metalloproteinases (Higasino et al. 1995; Kaya et al. 1996) and plasminogen activator (Nerlov et al. 1992; Wasylyk et al. 1992) , which participate in tumor invasion and metastasis. However, the biological functions of Ets-1 protooncogene remain unknown.
Several studies have reported the correlation of Ets-1 expression with invasiveness in various solid tumors such as breast carcinoma (Buggy et al. 2004; Katayama et al. 2005) , prostatic carcinoma (Alipov et al. 2005) , tongue carcinoma (Endo et al. 2006) , and also with poor prognosis (Davidson et al. 2001; Wilson et al. 2004 ). Ets-1 expression was also reported to correlate with tumor progression in patients with non-small cell lung carcinoma (Bolon et al. 1995; Sasaki et al. 2001; Takanami et al. 2001) . However, the relationship between Ets-1 expression and patient prognosis has not been assessed in great details.
We hypothesized that the Ets-1 protooncogene is associated with malignant behavior in lung carcinoma. To test our hypothesis, we examined the expression of Ets-1 proto-oncogene in human non-small cell lung carcinoma, and the relationship between such expression and histo-washing with FBS, the sample was incubated with the secondary antibody (alkaline phosphatase-conjugated horse anti-rabbit immunoglobulin) for one hour at room temperature. Visualization of immunoreaction was performed using a mixture of 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium chloride (BCIP/NBT; BRL, Gaithersburg, MD, USA). Preabsorption of the primary antibody with excess recombinant Ets-1 peptide (Santa Cruz Biotechnology) was used as the negative control. Tissue samples from the adrenal gland served as the internal positive control (Kola et al. 1993) for Ets-1 immunostaining. Cells that immunostained more strongly or as strong as positive controls were categorized as Ets-1-positive cells. Furthermore, samples in which positive cells constituted > 50% of tumor cells were considered Ets-1-positive cases.
Statistical analysis
Continuous data such as age and tumor size were expressed as mean. Differences between categorical data were examined for statistical significance using the Student's t-test, while differences in percentages were examined by the χ 2 test. Disease-free and overall survival rates, following surgical removal of the primary cancer, according to Ets-1 expression of the tumor, were calculated by the Kaplan-Meier method, and differences between groups were tested for significance using the log-rank test. The prognostic relevance of a single factor was determined by the multivariate Cox's proportional hazards regression model. A p value < 0.05 denoted the presence of a significant statistical difference. Statistical analyses were performed using SAS software (Statistical Analysis System Inc., Cary, NC, USA). Fig. 1 shows the pattern of immunohistochemistry of Ets-1 in lung carcinomas: squamous cell carcinoma (Fig. 1A) and adenocarcinoma (Fig. 1B) . Ets-1 expression was detected in the cytoplasm as well as the nucleus of cancer cells. Table 1 summarizes the relationship between expression of Ets-1 protein and gender, age, and histopathological type. Ets-1-positive tumors were significantly less common in females than males. There were no significant differences in age between patients with Ets-1-positive and Ets-1-negative tumors. A strong signal of Ets-1 was detected in almost 53% (82/156) of the carcinomas. The expression of Ets-1 was observed more frequently in squamous cell carcinoma (36/52; 69%) than in adenocarcinoma (41/96; 43%, p < 0.01). Table 2 shows the relationships between Ets-1 expression and pleural invasion and tumor staging. There were no significant differences in pleural invasion, tumor (t)-factor, node (n)-factor, metastasis (M)-factor, and TNM staging, based on the presence or absence of Ets-1 expression. Fig. 2 shows the correlation between the degree of tumor differentiation and Ets-1 expression in adenocarcinoma and squamous cell carcinoma. These results indicate that the progression of adenocarcinoma was associated with increased number of tumors positive for Ets-1. Thus, there was significantly more Ets-1-positive poorly-differentiated adenocarcinoma than Ets-1-positive well-and moderately-differentiated adenocarcinoma. In contrast, no such relationship was present between Ets-1 expression and degree of differentiation in squamous cell carcinomas. We also analyzed the relationship between subtypes of adenocarcinoma and expression of Ets-1 (Fig. 3) . Ets-1 expression was observed more fre- quently in acinar type than in papillary or alveolar type. Fig. 4 shows the correlation between tumor size and Ets-1 expression. The tumor size of Ets-1-positive adenocarcinoma was larger than that of negative cases.
RESULTS
Relationship between Ets-1 expression and clinicopathological features
Relationship between Ets-1 expression and patient survival
Fig . 5 shows the disease-free survival after pulmonary resection. Expression of Ets-1 tended to be associated with poorer disease-free survival in patients with adenocarcinoma than Ets-1-negative adenocarcinomas. Fig. 6 shows the overall survival after pulmonary resection. Expression of Ets-1 was significantly associated with poorer overall survival in patients with adenocarcinoma by the Log-rank test. Multivariate analysis of cases with adenocarcinoma indicated that the odds ratio of Ets-1 expression in diseasefree survival was 0.67 (95% confidence interval: 0.35-1.24, not significant), while the odds ratio of Ets-1 expression in the overall survival was 1.25 (0.83-1.95, not significant).
DISCUSSION
The major finding of the present study was that the expression of Ets-1 is a good marker of progression and prognosis of lung adenocarcinoma; the number of adenocarcinoma expressing Ets-1 increased with poor differentiation of the tumor and this expression correlated with poor survivals after resection. Ets-1 expression was also found to correlate with differentiation of other tumors (Yu et al. 2003; Keehn et al. 2004; Katayama et al. 2005) . These findings suggest that Ets-1 plays a role in the regulation of tumor cell differentiation.
Previous studies have also reported the expression of Ets-1 during embryonic life, particularly during morphogenesis such as organ formation in aves and mammals, including humans (Kola et al. 1993 ). In our study, Ets-1 expression was observed more frequently in acinar type adenocarcinoma than in papillary or alveolar type adenocarcinoma. Considered together, these findings suggest that Ets-1 is involved in mechanisms of morphological development not only in the embryo but also in carcinomas. Our results also showed that Ets-1-expressing adenocarcinomas were larger in size than Ets-1-negative tumors. Since Ets-1 is related to cell proliferation (Lewin 1991) , we postulate that Ets-1 has a growthpromotion action in lung adenocarcinoma. Suzuki et al. (1995) reported the presence of a variant type of Ets-1, and that wild type Ets-1, but not the variant type, suppressed tumorigenicity of human colon carcinoma cells. Recent studies have demonstrated loss of heterozygosity (LOH) of 11q23 in lung adenocarcinoma (Rasio et al. 1995) .
Our results also showed that Ets-1 was expressed more frequently in squamous cell carcinomas than in adenocarcinoma, but such expression did not correlate with differentiation or tumor size in squamous cell carcinomas. These findings suggest that overexpression of Ets-1 occurred at early stages of tumor progression. Bolon et al. (1995) reported that the expression of Ets-1 was scattered in lung carcinoma itself and that such expression was more frequently observed in tumors with neuroendocrine features. We also examined immunohistochemically whether lung tumors that expressed Ets-1 showed neuroendocrine properties or were small cell lung carcinomas. However, most carcinomas were negative for neuroendocrine features (data not shown). Thus, Ets-1 expression was different in each histopathological type of lung carcinomas.
The expression of Ets-1 has been identified in various neoplasms including lung carcinoma (Bolon et al. 1995) , stomach (Nakayama et al. 1996; Yu et al. 2003) , pancreas (Ito et al. 1998) , liver (Ozaki et al. 2000) , esophagus (Saeki et al. 2000) , ovary (Davidson et al. 2001) , breast (Buggy et al. 2004; Katayama et al. 2005) , tongue (Endo et al. 2006) , and prostate (Alipov et al. 2005) . In these studies, it was speculated that Ets-1 might be involved not only in tumor invasion but also in remodeling of connective tissue. Therefore, it is important to investigate whether Ets-1 is expressed in tumor cells only or also in stromal cells. In our study, Ets-1 expression was more common and stronger in tumor cells themselves but not in stromal cells (not shown in the Figure) . There is a controversy on the cellular distribution of Ets-1. A number of investigators have reported that Ets-1 protein is localized in both the nucleus and cytoplasm (Watson et al. 1990) , while other investigators reported the predominant localization of Ets-1 protein in the nucleus (Pognonec et al. 1989) . In the present study, we found Ets-1 protein in both the cytoplasm and nucleus. Ets-1 protein binds to a specific sequence on DNA in the nucleus and therefore its presence in the cytoplasm may reflect overproduction of Ets-1. Ets-1 is regulated by not only RNA processing control such as alternative splicing (Kiozumi et al. 1990 ), but protein activity control such as phosphorylation (Pognonec et al. 1989 ). These results emphasize the need to evaluate the activity of Ets-1 expressed in neoplastic cells.
In our study, Ets-1 expression did not correlate with TNM staging, however, our study showed that Ets-1-expressing tumors were larger in size compared with Ets-1-negative adenocarcinomas. There is controversy regarding the correlation between Ets-1 expression and tumor stage. For example, Ets-1 mRNA level did not correlate with clinical stage and T factor (Sasaki et al. 2001 ). However, the mRNA level in tumors with lymph node metastasis was higher than nodenegative tumors. In our study, Ets-1 expression analyzed by immunohistochemistry was not associated with status of lymph node metastasis. Difference in analytical techniques could explain the different results of Sasaki et al. (2001) and the present study. Furthermore, the sample size in our study was larger than in their series. In contrast to these results, Takanami et al. (2001) reported that Ets-1 expression analyzed by immunohistochemistry correlated with T factor, node status and tumor stage. The above two previous studies were performed in lung adenocarcinomas only while our study included adenocarcinoma and other histopathological types of lung carcinoma. Our present data showed that Ets-1 expression was more frequent in squamous cell carcinoma and was also observed in large cell carcinoma. In previous studies, the expression or activity of Ets-1 was reported to be regulated by various factors such as c-Myc (Vandenbunder et al. 1989 ), c-Myb (Desbiensm et al. 1991) , tumor necrosis factor-α (Wernert et al. 1994) , basic fibroblast growth factor (Wernert et al. 1994) , Ras (Yang 1996) , and platelet-derived growth factor (Hultgårdh-Nilsson et al. 1996) . Furthermore, Ets-1 also regulates the expression of various enzymes, growth factors, oncogenes, lymphokines such as matrix metalloproteinases (Wasylyk et al. 1992) , urokinase-type plasminogen activator (Nerlov et al. 1991) , α 4-integrin (Rosen et al. 1994) , granulocyte-macrophage colony stimulating factor (Thomas 1995) , interleukin 2 (RomanoSpica 1995), and p53 (Venanzoni 1996) . Several factors are involved in progression of tumors and it is therefore unlikely that only Ets-1 determines the staging of the tumor.
Ets-1 expression was reported to correlate with patient survival in ovarian carcinomas (Davidson et al. 2001) . Although Ets-1 expression was associated with tumor progression and invasion, the relationship with patient survival after surgical treatment in various carcinomas including lung carcinomas has not been assessed fully. In the present study, such expression tended to be associated with disease-free and overall survivals in patients with lung adenocarcinoma who underwent pulmonary resection, and this finding is similar to those of a previous report (Takanami et al. 2001) . On the other hand, such expression did not correlate with survival in squamous cell carcinomas of the lung. Since Ets-1 expression did not correlate with tumor stage, in contrast to previous reports (Sasaki et al. 2001) , it is possible that Ets-1 expression is an independent prognostic marker. Although Ets-1 expression was not identified as a significant prognostic parameter in lung adenocarcinoma by multivariate analysis in the present study, it remains a potentially useful prognostic marker because of the small number of patients with adenocarcinoma. Further study based on the larger number of subject would be necessary to clarify this issue.
In conclusion, the present report describes the correlation between Ets-1 expression and histopathological type, differentiation, subtype, tumor size, and TMN-staging in non-small cell lung cancers. Ets-1 expression was more frequent in males, and squamous cell carcinoma than in females and adenocarcinoma. Ets-1 expression correlated with histopathological differentiation, histopathological subtype and tumor size in lung adenocarcinomas but not with tumor stage. Ets-1 expression tended to be associated with poor disease-free and overall survivals in patients with lung adenocarcinoma. Investigation of the multiple functions of Ets-1 would be useful to understand the complex process of tumor progression and this expression may be a useful prognostic marker of lung adenocarcinoma after surgical resection.
